Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00002890
First received: November 1, 1999
Last updated: June 24, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2001
  Primary Completion Date: January 2001 (Final data collection date for primary outcome measure)